Dr. Jason Hafron, Chief Medical Officer of the Michigan Institute of Urology, provides a detailed real-world explanation of reimbursement considerations for Jelmyto (mitomycin) in treating upper tract urothelial carcinoma: coverage, coding, and payment.
Jelmyto Administration and Reimbursement in Your Practice
By Jason Hafron, MD - Last Updated: October 2, 2024
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.